agilon health, inc. (AGL) Stock Price & Analysis

agilon health, inc. (AGL) closed at USD 90.29 on Thursday, October 22, 2026, down 0.77% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 90.99; the Oct 22, 2026 session ranged USD 87.69–92.7 on volume of 184,309 shares. Market capitalization is $1.52B, with a 52-week range of USD 7.48–133.04 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:22 UTC.

Also available as compact Markdown for AI agents: nexqual.com/AGL.md

Key facts (AGL)

• Last four reported quarters (through Jun 30, 2026): revenue $5.92B, net income -$232M (-3.9% margin), free cash flow -$85.0M (SEC filings).
• 1 of 80 tracked superinvestors hold AGL (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
• Total return with dividends: 1Y +266.3% vs S&P 500 +14.9%; 5Y -84.8% vs S&P 500 +80.3%.
• Next earnings: 2026-11-04, EPS estimate USD -0.73, revenue estimate $1.46B.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (AGL)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (AGL)

Superinvestors (SEC 13F-HR, Q2 2026) (AGL)

1 of 80 tracked investors hold AGL. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Analysts (AGL)

Rating changes, last 120 days:

Total return (dividends reinvested) (AGL)

AGL revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

AGL suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 25, 2026.

AGL customer concentration

In the period ended Jun 30, 2026, 2 direct customers each accounted for at least 10% (25%, 20%) of revenue, per the company's 10-Q filed Aug 5, 2026. The company does not name them.

AGL company outlook (results filed Aug 5, 2026)

• “Revenue was favorable due to higher than expected burden of illness performance, payor contracting, and improved pricing partially offset by lower year-over-year membership. • Gross profit was $107 million in the second quarter 2026 compared to gross loss of $52 million in the second quarter 2025.”

Quoted word-for-word from the SEC 8-K results press release.

AGL analyst estimates and revisions

Key Statistics (as of October 23, 2026 at 09:22 UTC)

Technical Analysis (AGL)

Nexqual's technical model rates AGL "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:22 UTC.

Earnings (AGL)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:22 UTC.

Financials & Fundamentals (AGL)

Source: Nexqual, October 23, 2026 at 09:22 UTC.

Ownership (AGL)

Source: Nexqual, October 23, 2026 at 09:22 UTC.

From agilon health, inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• We have proprietary technology and processes that support our operational programs and clinical insights, including our "CORE" technology platform, HCC Manager risk adjustment software application, and Minerva clinical data platform, all of which are proprietary systems that aid in the aggregation and analysis of third-party data we collect.
• We rely on a combination of international and U.S. trademark law as well as confidentiality procedures and contractual provisions to protect our trade secrets, including proprietary technology, databases and our brand.
• Through this partnership, our physician partners' existing MA patient panels are attributed to our platform through our subscription-like per-member per-month ("PMPM") agreements with payors.
• In certain cases, our anchor physician groups may be entitled to a guaranteed minimum FFS base compensation rate from the RBE in the event that the FFS base compensation rate paid by the health plan payor does not meet the negotiated base compensation rate as agreed between the RBE and the anchor physician group, or if the FFS base compensation rate paid by the health plan payor falls below what the anchor physician group had received prior to joining our platform.

Partnerships

• The ACO may terminate its participation agreement with CMS at any time upon advance written notice.
• Our company was formed in 2016, and we established our inaugural partnership with an anchor physician group in 2017.

Legal & Regulatory Risks (Item 1A, quoted)

• Our estimates of our members' risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts could be inaccurate.
• Government funding for healthcare programs is subject to statutory and regulatory changes, administrative rulings, interpretations of policy and determinations by intermediaries and governmental funding restrictions, all of which could materially impact program coverage and reimbursements for both institutional and professional services.
• Regulatory proposals directed at containing or lowering the cost of healthcare, including the ACO REACH Model, and our participation, voluntary or otherwise, in such proposed models, could impact our business, financial condition, cash flows and operations.
• We, as well as our physician partners and affiliates, have in the past, and could in the future, be subject to federal and state investigations, audits and enforcement actions.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:22 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt